Terms: = Ovarian cancer AND MYD88, Q99836, MYD88D, 4615
49 results:
1. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract] [Full Text] [Related]
2. [Expression of lnc-myd88 and its relationship with the prognosis of patients with epithelial ovarian cancer].
Zhu Y; Huang JM; Zhang GN; Li JM; Huang J
Zhonghua Fu Chan Ke Za Zhi; 2022 Feb; 57(2):117-124. PubMed ID: 35184472
[No Abstract] [Full Text] [Related]
3. The role of the MAD2-TLR4-myd88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract] [Full Text] [Related]
4. The role of Toll-like receptor 4 signaling pathway in ovarian, cervical, and endometrial cancers.
Lupi LA; Cucielo MS; Silveira HS; Gaiotte LB; Cesário RC; Seiva FRF; de Almeida Chuffa LG
Life Sci; 2020 Apr; 247():117435. PubMed ID: 32081661
[TBL] [Abstract] [Full Text] [Related]
5. P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in ovarian cancer SKOV-3 Cells: A Preliminary Study.
Lupi LA; Delella FK; Cucielo MS; Romagnoli GG; Kaneno R; Nunes IDS; Domeniconi RF; Martinez M; Martinez FE; Fávaro WJ; Chuffa LGA
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861351
[TBL] [Abstract] [Full Text] [Related]
6. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in ovarian cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract] [Full Text] [Related]
7. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
Zandi Z; Kashani B; Poursani EM; Bashash D; Kabuli M; Momeny M; Mousavi-Pak SH; Sheikhsaran F; Alimoghaddam K; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2019 Jun; 853():256-263. PubMed ID: 30930249
[TBL] [Abstract] [Full Text] [Related]
8. Nucleoside Diphosphate Kinase-3 (
Flentie K; Gonzalez C; Kocher B; Wang Y; Zhu H; Marasa J; Piwnica-Worms D
Mol Cancer Res; 2018 Jun; 16(6):986-999. PubMed ID: 29523766
[TBL] [Abstract] [Full Text] [Related]
9. myd88 and TLR4 Expression in Epithelial ovarian cancer.
Block MS; Vierkant RA; Rambau PF; Winham SJ; Wagner P; Traficante N; Tołoczko A; Tiezzi DG; Taran FA; Sinn P; Sieh W; Sharma R; Rothstein JH; Ramón Y Cajal T; Paz-Ares L; Oszurek O; Orsulic S; Ness RB; Nelson G; Modugno F; Menkiszak J; McGuire V; McCauley BM; Mack M; Lubiński J; Longacre TA; Li Z; Lester J; Kennedy CJ; Kalli KR; Jung AY; Johnatty SE; Jimenez-Linan M; Jensen A; Intermaggio MP; Hung J; Herpel E; Hernandez BY; Hartkopf AD; Harnett PR; Ghatage P; García-Bueno JM; Gao B; Fereday S; Eilber U; Edwards RP; de Sousa CB; de Andrade JM; Chudecka-Głaz A; Chenevix-Trench G; Cazorla A; Brucker SY; ; Alsop J; Whittemore AS; Steed H; Staebler A; Moysich KB; Menon U; Koziak JM; Kommoss S; Kjaer SK; Kelemen LE; Karlan BY; Huntsman DG; Høgdall E; Gronwald J; Goodman MT; Gilks B; García MJ; Fasching PA; de Fazio A; Deen S; Chang-Claude J; Candido Dos Reis FJ; Campbell IG; Brenton JD; Bowtell DD; Benítez J; Pharoah PDP; Köbel M; Ramus SJ; Goode EL
Mayo Clin Proc; 2018 Mar; 93(3):307-320. PubMed ID: 29502561
[TBL] [Abstract] [Full Text] [Related]
10. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract] [Full Text] [Related]
11. Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance.
Edwardson DW; Boudreau J; Mapletoft J; Lanner C; Kovala AT; Parissenti AM
PLoS One; 2017; 12(9):e0183662. PubMed ID: 28915246
[TBL] [Abstract] [Full Text] [Related]
12. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1).
Saif MW; Heaton A; Lilischkis K; Garner J; Brown DM
Cancer Chemother Pharmacol; 2017 Feb; 79(2):303-314. PubMed ID: 28013349
[TBL] [Abstract] [Full Text] [Related]
13. Adipocyte microenvironment promotes Bcl
Cardenas C; Montagna MK; Pitruzzello M; Lima E; Mor G; Alvero AB
Apoptosis; 2017 Apr; 22(4):558-569. PubMed ID: 28012060
[TBL] [Abstract] [Full Text] [Related]
14. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
[TBL] [Abstract] [Full Text] [Related]
15. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract] [Full Text] [Related]
16. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and myd88 and related proteins.
Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
[TBL] [Abstract] [Full Text] [Related]
17. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in ovarian cancer Stem Cells and Prevents Recurrence In Vivo.
Alvero AB; Heaton A; Lima E; Pitruzzello M; Sumi N; Yang-Hartwich Y; Cardenas C; Steinmacher S; Silasi DA; Brown D; Mor G
Mol Cancer Ther; 2016 Jun; 15(6):1279-90. PubMed ID: 27196760
[TBL] [Abstract] [Full Text] [Related]
18. Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated myd88/NF-κB signaling in vitro.
Liu H; Zhang G; Huang J; Ma S; Mi K; Cheng J; Zhu Y; Zha X; Huang W
J Transl Med; 2016 Apr; 14(1):104. PubMed ID: 27118139
[TBL] [Abstract] [Full Text] [Related]
19. ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012.
Trétarre B; Molinié F; Woronoff AS; Bossard N; Bessaoud F; Marrer E; Grosclaude P; Guizard AV; Delafosse P; Bara S; Velten M; Lapôtre-Ledoux B; Ligier K; Léone N; Arveux P; Uhry Z
Gynecol Oncol; 2015 Nov; 139(2):324-9. PubMed ID: 26383829
[TBL] [Abstract] [Full Text] [Related]
20. Molecular Consequences of Proprotein Convertase 1/3 (PC1/3) Inhibition in Macrophages for Application to cancer Immunotherapy: A Proteomic Study.
Duhamel M; Rodet F; Delhem N; Vanden Abeele F; Kobeissy F; Nataf S; Pays L; Desjardins R; Gagnon H; Wisztorski M; Fournier I; Day R; Salzet M
Mol Cell Proteomics; 2015 Nov; 14(11):2857-77. PubMed ID: 26330543
[TBL] [Abstract] [Full Text] [Related]
[Next]
